Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Gefitinib is a selective tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) used to treat adults with EGFR mutation-positive non-small-cell lung cancer (NSCLC). Clinical benefits of gefitinib administration in NSCLC patients have been observed in clinical practice, but the exte...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Dongsheng, Zhang, Guobing, Zhang, Xingguo, Lian, Xingguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
7200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782910/
https://www.ncbi.nlm.nih.gov/pubmed/26945426
http://dx.doi.org/10.1097/MD.0000000000003008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782910/
https://www.ncbi.nlm.nih.gov/pubmed/26945426
http://dx.doi.org/10.1097/MD.0000000000003008

Ejemplares similares